Blue Water Acquisition Corp. III Unit.
BLUW evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BLUW—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BLUW
Blue Water Acquisition Corp. III is a blank check company (SPAC) focused on a business combination in biotechnology, healthcare, or technology; it has not commenced operations and relies on trust account income for net income, with a working capital deficit and substantial doubt about its ability to continue as a going concern.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Blue Water Acquisition Corp. III is a blank check company (SPAC) focused on a business combination in biotechnology, healthcare, or technology; it has not commenced operations and relies on trust account income for net income, with a working capital deficit and substantial doubt about its ability to continue as a going concern.
- As of June 30, 2026, the company had $0.0M in cash and equivalents and a working capital deficit of $627,254 [sec_mda · as of 2026-08-12].
- Net income for the six months ended June 30, 2026 was $4,023,115, driven primarily by $4,574,624 of interest income on the trust account [sec_mda · as of 2026-08-12].
- The company has not commenced any operations and will not generate operating revenues until after completing an initial business combination [sec_mda · as of 2026-08-12].
- Management has expressed substantial doubt about the company's ability to continue as a going concern one year from the issuance date of its financial statements [sec_mda · as of 2026-08-12].
- The company expects expenses to increase substantially after identifying a target for its initial business combination [sec_mda · as of 2026-08-12].
What works
- The company generates non-operating income from interest on cash and marketable securities held in the Trust Account, which has produced net income in recent periods [sec_mda · as of 2026-08-12].
- The Sponsor is committed to extending Working Capital Loans as needed to support operations [sec_mda · as of 2026-08-12].
What to weigh
- The company has a working capital deficit of $627,254 as of June 30, 2026 and no cash equivalents [sec_mda · as of 2026-08-12].
- Management has identified substantial doubt about the company's ability to continue as a going concern within one year [sec_mda · as of 2026-08-12].
- The company has not yet identified or completed a business combination and faces uncertainty in consummating one [sec_mda · as of 2026-08-12].
- Expenses are expected to increase substantially after a target is identified, adding financial pressure [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
The company had no cash equivalents and a working capital deficit as of June 30, 2026.
“respectively, no cash equivalents, and a working capital deficit of $627,254 and $109,004, respectively.”
SEC MD&A · August 12, 2026
Net income for the six months ended June 30, 2026 was driven by interest income on the trust account.
“Net income of $4,023,115 was increased by a $84,069 increase in operating assets and liabilities, offset by $4,574,624 of interest income on the trust account.”
SEC MD&A · August 12, 2026
The company has not commenced any operations.
“As of June 30, 2026, the Company has not commenced any operations.”
SEC MD&A · August 12, 2026
There is substantial doubt about the company's ability to continue as a going concern.
“These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern one year from the date these unaudited condensed financial statements are issued.”
SEC MD&A · August 12, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Management has raised substantial doubt about the company's ability to continue as a going concern within one year [sec_mda · as of 2026-08-12].
- No operating revenues — The company has not commenced operations and will not generate operating revenues until after a business combination [sec_mda · as of 2026-08-12].
- Working capital deficit — As of June 30, 2026, the company had a working capital deficit of $627,254 and no cash equivalents [sec_mda · as of 2026-08-12].
- Dependence on sponsor loans — The company relies on the Sponsor's commitment to extend Working Capital Loans, but no formal agreement exists [sec_mda · as of 2026-08-12].
What to watch
- Whether the company identifies and announces a target for an initial business combination [sec_mda · as of 2026-08-12].
- Changes in the company's cash position and working capital status in future filings [sec_mda · as of 2026-08-12].
- Any updates on the Sponsor's continued financial support through Working Capital Loans [sec_mda · as of 2026-08-12].
- The company's ability to resolve the going concern uncertainty within the next year [sec_mda · as of 2026-08-12].
Sources: SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run Blue Water Acquisition Corp. III Unit. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Blue Water Acquisition Corp. III Unit. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
0.5 months
OCF -$388K · Net income $2M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Short Interest
- % of float
- -
- Days to cover
- —
- Shares short
- -
- Daily short volume (Aug 28, 2026)
- 8.4%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BLUW short interestFrequently asked questions
What is the AI investment thesis for Blue Water Acquisition Corp. III Unit.?
Blue Water Acquisition Corp. III is a blank check company (SPAC) focused on a business combination in biotechnology, healthcare, or technology; it has not commenced operations and relies on trust account income for net income, with a working capital deficit and substantial doubt about its ability to continue as a going concern.
Who is the CEO of Blue Water Acquisition Corp. III Unit.?
Mr. Kevin J. McGurn is the chief executive officer of Blue Water Acquisition Corp. III Unit. (BLUW).
Where is Blue Water Acquisition Corp. III Unit. headquartered?
Blue Water Acquisition Corp. III Unit. (BLUW) is headquartered in Mountainside, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.